License Agreements - Additional Information (Details) - USD ($) $ in Thousands |
3 Months Ended | |||
---|---|---|---|---|
Mar. 31, 2023 |
Mar. 31, 2022 |
Dec. 31, 2022 |
Jul. 31, 2022 |
|
Research And Development Arrangement Contract To Perform For Others [Line Items] | ||||
Research and development expenses | $ 47,110 | $ 24,490 | ||
Common stock shares issued | 61,863,010 | 61,730,816 | 1,519,756 | |
Issuance of common stock, value | $ 62 | $ 62 | ||
Harvard and Board | ||||
Research And Development Arrangement Contract To Perform For Others [Line Items] | ||||
Success payment liability | 300 | |||
Payment of milestone development | 23,100 | |||
Payment of sales based milestone | 54,000 | |||
Beam License Agreement | ||||
Research And Development Arrangement Contract To Perform For Others [Line Items] | ||||
Research and development expenses | 0 | $ 0 | ||
Novartis license agreement [Member] | ||||
Research And Development Arrangement Contract To Perform For Others [Line Items] | ||||
Payment of sales based milestone | 35,000 | |||
Clinical And Regulatory Milestone | 10,000 | |||
Milestone related expenses | $ 0 |